Earnings Report·May 4, 2026
Twist Bioscience (NASDAQ: TWST) Drops on Wider EPS Loss Despite Revenue Beat
Stock plummets 7% after Q2 revenue beat offset by widening operating losses and negative per-share earnings.
Twist Bioscience Corporation (NASDAQ: TWST) Stock News & Analysis
Twist Bioscience Corporation (NASDAQ: TWST) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight tracks TWST across all major catalysts: quarterly earnings reports, analyst upgrades and downgrades, mergers and acquisitions, regulatory decisions, and significant price moves driven by sector or macro developments. This page centralises 2 articles published since May 4, 2026, providing investors with timely, data-driven analysis of Twist Bioscience Corporation's financial performance and competitive position. New coverage is added each trading day.
TWST Coverage -- 2 Articles
Health Care·Monday, June 15, 2026
Canaccord Genuity Starts Twist Bioscience (TWST) at Buy With $90 Price Target
Canaccord Genuity sets a $90 price target on TWST, implying double-digit upside from current levels as analyst Kyle Mikson opens coverage with a Buy rating.
3 min readRead article
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.